Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy
| Autor: | Maurizio Cutolo, Patrizia Zentilin, F. Indiveri, Alberto Sulli, Giuseppe Murdaca, F. Ropolo, R. Gianrossi, Gilberto Filaci, Francesco Puppo, C. Castagneto, Massimo Ghio, L. Derchi, Marco Scudeletti |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent medicine.medical_treatment Enzyme-Linked Immunosorbent Assay Gastroenterology Rheumatology Internal medicine Cyclosporin a Immunopathology medicine Humans Pharmacology (medical) Iloprost Child Aged Chemotherapy Scleroderma Systemic business.industry Interleukin-6 Therapeutic effect Middle Aged medicine.disease Ciclosporin Connective tissue disease Surgery Cyclosporine Platelet aggregation inhibitor Drug Therapy Combination Female business Immunosuppressive Agents Platelet Aggregation Inhibitors medicine.drug |
| Zdroj: | Rheumatology (Oxford, England). 38(10) |
| ISSN: | 1462-0324 |
| Popis: | Objectives. The main aim was to analyse the long-term therapeutic effects on systemic sclerosis (SSc) patients of treatment with either (i) iloprost alone or (ii) low-dose oral cyclosporin A (CyA) associated with iloprost. A secondary aim was to analyse interleukin-6 (IL-6) serum levels in SSc patients before and after 1 yr of treatment. Methods. A clinical trial was performed in which 20 consecutive SSc patients were alternately randomized into two homogeneous groups receiving either monthly i.v. iloprost (1 ng/kg/min in 6 h i.v. infusion, for 5 consecutive days, I week per month) (Group I) or low-dose CyA (2.5 mg/kg/day) associated with iloprost administration (Group II). IL-6 concentrations were evaluated by ELISA in the sera of each patient before and after 1 yr of therapy and in 20 healthy subjects. Results. After 1 yr of therapy, a significant improvement of skin (P = 0.008), microvascular (P = 0.004) and oesophageal (P = 0.05) morphological and functional parameters was observed only in Group II patients. Furthermore, after 1 yr of treatment, a significant reduction (P = 0.007) of IL-6 serum concentration was observed only in Group II patients. Conclusions. Collectively, our data suggest that the combination of low-dose CyA with iloprost administration may be of clinical utility in SSc and that a mechanism of action of CyA in SSc may include the decrease in IL-6 production. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|